An inhibitor of PIK3CA, alpelisib, has been approved for the treatment of hormone-positive HER2-negative (HR+HER2-) breast cancer, in which PIK3CA, the gene encoding p110a, is frequently mutated. Here, PIK3CA is linked to breast cancer.